Actively Recruiting
Randomized, Double-Blind Study Evaluating Telitacicept Versus Placebo for Adults with Active Primary Sjogrens Disease
Led by Vor Biopharma · Updated on 2026-10-19
250
Participants Needed
49
Research Sites
4 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating telitacicept, a recombinant fusion protein targeting B-cell pathways, in adults with active primary Sjogrens disease. This phase 3 trial explores telitacicepts potential to reduce B-cell activity and autoimmune effects contributing to disease symptoms. The study compares telitacicept with a placebo to assess its impact on disease activity and patient well-being. Participants are randomly assigned to receive either telitacicept or placebo via subcutaneous injection. The study is double-blind, meaning neither participants nor researchers know who receives which treatment. The primary treatment period lasts 48 weeks, during which the effects on disease activity and gland function are evaluated. Throughout the study, participants undergo assessments including the EULAR Sjogrens Syndrome Disease Activity Index ESSDAI, patient and physician disease activity evaluations, fatigue assessment, and gland function tests. Safety and efficacy are monitored regularly, with the primary outcome measured at Week 48. The total study duration extends until January 2029, allowing comprehensive evaluation of telitacicepts effects.
CONDITIONS
Brief Title
Phase 3 Study of Telitacicept in Active Primary Sjögren's Disease
Research Team
J
Jeremy Sokolove
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here